NK cells are functionally controlled by the killer immunoglobulin-like receptor (KIR) family that comprises inhibitory (iKIR) and activating (aKIR) members. Genetic association studies suggest that donors expressing aKIRs next to iKIRs will be superior donors in the setting of hematopoietic stem cell transplantation of patients with leukemia. However, contrary evidence states that aKIR expression may be irrelevant or even detrimental. Using a complex methodology incorporating KIR-Q-PCR, double fluorescence and viSNE analysis, we characterized subset distribution patterns and functionality in haplotype A donors which lack aKIRs and haplotype B donors that express a variety of B-specific genes. Here, we show that the alloreactive KIR2DS1 + NK cell subset in HLA-C1/ C2 donors is highly responsive towards C2-expressing targets but quantitatively small and as such does not significantly contribute to cytotoxicity. Thus, we fail to find a direct link between haplotype allocation status and NK cell cytotoxicity at least in HLA-C1/C2 heterozygous donors.
Introduction
NK cells are functionally controlled by the HLA class I-restricted killer immunoglobulin-like receptor (KIR) family that comprises both inhibitory (iKIR) and activating (aKIR) family members which recognize allotypic variants of HLA class I alleles (KIRL). Depending on the absence or presence of aKIRs, two haplotypes are distinguished: haplotype A donors express a canonical iKIR gene content while haplotype B donors have a variable gene content with one or more of the B-specific genes (KIR2DS1, 2, 3, 5, KIR3DS1, KIR2DL2 and/or KIR2DL5) (1) . Genetic association studies suggest that a donor who provides an iKIR-KIRL mismatch towards the recipient (2) , but who also possesses aKIRs (3, 4) and who ideally expresses multiple aKIRs (3, 5) , will be the potentially 'optimal' donor in the setting of hematopoietic stem cell transplantation (HSCT) to treat patients with leukemia as NK cell-mediated graft-versus-leukemia (GvL) effects are maximally exploited.
However, controversy exists about the usefulness to select a donor based on genetically predicted determinants of NK cell alloreactivity. This may in part be explained by the fact that the prediction of alloreactivity by HLA/KIR genotyping alone does not incorporate information on the actual size of the alloreactive subset which differs considerably from donor to donor (6) and the circumstance that discrepancies may exist between KIR genotype and protein expression (7) . Moreover, only few studies have been able to directly document a binding of aKIRs to HLA class I molecules, presumably as a result of weak or sometimes even non-existent binding. So far, KIR2DS1 is the only aKIR known to play a clinically relevant role in the context of alloreactivity and tolerance. In this regard, it has been shown that KIR2DS1 is able to recognize HLA-C2-expressing targets and to mediate alloresponses (8) (9) (10) ; however, its binding affinity is distinctly lower than that of its inhibitory counterpart KIR2DL1 (11) . In addition, aKIRs are assumed to be a subject of education to prevent autoimmunity and, in line with this, it has been demonstrated in HLA-C2 homozygous hosts that KIR2DS1
− NK cells are hyporesponsive (12, 13) .
Thus, we face the situation in which genetic association studies suggest a clinical benefit of 'multiple aKIR' expression; however, a sound scientific basis to document this is missing. Using expanded NK cell preparations of HLA-C1/C2 heterozygous donors as effectors and the HLA-C2-transfected B lymphoblastoid L721.221-cw*0602 cell line as a target, we here apply a complex methodology incorporating KIR-Q-PCR, double fluorescence analysis and viSNE analysis to pursue the question of how large the alloreactive KIR2DS1 + NK cell subset actually is and to what extent it contributes to NK cell cytotoxicity.
Methods

NK cell expansion procedure
PBMCs from volunteer HLA-C1/C2 donors were subjected to sequence-based four-digit resolution [sequence-based typing (SBT)] typing in accordance with the Declaration of Helsinki (Supplementary Table 1 , available at International Immunology Online). NK cells were activated and expanded as described before using the HLA-null K562-mbIL15-41BBL transfectant (14, 15) . Prior to experiments, these expanded NK cells [NK cell activation and expansion (NKAES)] were cultured overnight in the presence of 100 IU ml −1 IL-2 for in vitro cytotoxicity assays or characterization experiments and 200 IU ml −1 IL-2 for functional response staining.
Cell lines
K562-mbIL15-41BBL cells (14) and L721.221-cw*0602 (16) were maintained at 0.1-0.5 × 10 6 cells ml −1 in RPMI-1640 containing 10% FCS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin and 2 mM l-glutamine or rather RPMI-1640 containing 10% FCS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin, 2 mM l-glutamine and 1 mM pyruvate and selected by 0.4 mg ml −1 hygromycin B resistance.
KIR genotyping and haplotype group assignment
KIR genotyping was performed as previously described (15) . The B content score, the KIR genotype group assignment and the centromeric and telomeric gene content motif assignment were assessed as previously described (3). (12, 18) .
Flow cytometry
Determination of in vitro cytotoxicity
The target cell line L721.221-cw*0602 was labeled with 0. viSNE analysis viSNE maps (bh-SNE1/bh-SNE2) were calculated with the default settings (Barnes-Hut approximation, using no_dims = 2, perplexity = 30.000000, and theta = 0.500000) of the interactive visualization tool cyt (19) and exported as FCS 2.0 files. Each file was subsampled with cyt and a sample size of ~10 000 or 4881 events per donor was included for the viSNE analysis. All 12 donors were run in the same viSNE analysis to enable direct comparison between the donor groups. The following parameters were included: KIR2DL1/S5, KIR2DL1/S1, KIR2DL2/L3/ S2, KIR2DS3/S4, KIR3DL1, KIR3DL2, perforin and CD107a. Scale of X and Y axis: fixed from −40 to 40 or −50 to 50; color scale: 0 (blue) to 600 (red).
Statistics
Statistical evaluation was performed using GraphPad Prism version 6 (La Jolla, CA, USA), applying the two-tailed Mann-Whitney test for comparison of the two haplotype groups of non-paired data. Significant values were defined as P ≤0.05.
Results and discussion
To answer the question of to what extent aKIRs contribute to NK cell cytotoxicity, we selected six HLA-C1/C2 heterozygous haplotype A and B donors (Supplementary Table 1, available at International Immunology Online), knowing that KIR2DS1 is subject to education only in HLA-C2 homozygous but not heterozygous donors (12, 13) . Given that the activating KIR2DS1 is able to directly recognize C2 epitopes (8-11, 20, 21) , we chose only haplotype B donors with geno-and phenotypically detectable KIR2DS1 (Supplementary Table 2 and Figure S1 , available at International Immunology Online) and selected L721.221-cw*0602 cells as the target cell line which expresses a HLA-C2 epitope but notably also other important NK cell receptor ligands (Supplementary Figure S2A and Interestingly, in vitro cytotoxicity assays evidenced that haplotype A and B donors have a comparable ability for cytotoxicity (Fig. 1A) Fig. 2A and B Given is the internal de-identification code of the NK cell donors (SNK), the donor-specific KIR repertoire [as determined by (Q)-PCR] relevant for characterization of the alloreactive subset (38, 39) and the identification of the educated KIRs that are specific for the missing KIRL in the target cells. The following KIRs have been excluded from this table: KIR2DL4, which is expressed by all donors (data not shown) and which recognizes HLA-G; KIR3DS1, which is not considered as 'classical' alloreactive KIR; and KIR2DS4, which is to a large extent a soluble receptor that does not recognize cw*0602. (Fig. 3A) . However, when analyzing the bulk alloreactive NK cell pool (Fig. 3B) , the alloreactive − subset which may express other KIRs next to KIR2DS1 (Fig. 3C) or the total CD56 + CD3
− NK cell pool (Fig. 3D) , we did not see any differences whatsoever in the ability for degranulation or perforin synthesis upon coculture with L721.221-cw*0602 cells. Thus, we show that the alloreactive KIR2DS1
− NK cell subset in HLA-C1/C2 donors is functionally highly responsive but quantitatively very small. In this, we fail to obtain a proof for the biological basis of aKIR functionality in HLA-C1/C2 donors but instead demonstrate that alloreactive NK cells of haplotype A and B donors do not differ in their net ability to exert cytotoxicity towards a C2-expressing target cell line. Considering the substantial evidence that MHC class I expression is partially or completely lost in various tumor types, we at this point assume that the alloreactivity of the KIR2DS1 + NK cell subset will even be lower when studied towards primary tumor specimens.
Without doubt, there is sound epidemiologic evidence for a beneficial effect of aKIR expression obtained in large cohort studies (3) (4) (5) . However, contrary evidence also exists that − NK cell pool. Note, that despite the high CD107a expression of the KIR2DS1 + alloreactive NK cell subset, the overall capacity of haplotype B donor NK cells for degranulation and perforin secretion is comparable to haplotype A donors. Percentages in A-D are normalized to the corresponding baseline levels of expanded NK cells cultured in control medium only. As NK cell degranulation is accompanied with a decline in perforin levels, the numbers are negative.
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aKIR expression may either be irrelevant or even detrimental (23) (24) (25) (26) (27) . To make the matter even more complicated, aKIRs do not only mediate GvL effects but also contribute to the prevention of cytomegalovirus (CMV) re-activation (28, 29) and may reduce the incidence of graft-versus-host disease (GvHD) (23, 30) . Thus, we have to consider the possibility that the benefits associated with the haplotype B status are not necessarily attributable to aKIR-mediated GvL effects. As CMV infection itself stably imprints the KIR repertoire (31) and as such promotes the clonal expansion of an NKG2C + aKIR + NK cell compartment (32, 33) , it is conceivable that such an augmented alloreactive NK cell pool will indeed exert clinically relevant 'secondary or induced' GvL effects. In line with these thoughts, transplantation from 69 KIR2DS1 + and/or KIR3DS1-expressing donors was associated with a reduced risk of non-relapse mortality which was largely infection-related (34) . With respect to the pathophysiologic origin of GvHD occurrence, it has been speculated that the improved clinical outcome in haplo-HSCT with KIR2DS1-expressing donors may to a lesser degree be a result of improved NK cell cytotoxicity but rather a result of increased NK cell-mediated killing of C2/ C2 or C1/C2 dendritic cells (DCs) and allogeneic T cells (20) . In addition, the acquisition of the chemokine receptor CCR7 by NK cells is KIR2DS1-dependent and essentially results in increased migratory properties of NK cells to recipient lymph nodes which may prevent priming of recipient's T cells (35) .
With this publication, we do not want to question the genetic association data obtained in large cohort studies; however, we here fail to find a direct link between KIR2DS1 expression and NK cell-mediated GvL effects at least in HLA-C1/C2 heterozygous donors. Given the strong linkage disequilibrium of KIR2DS1 to KIR3DS1 (36) but also KIR3DL1, KIR2DL4 and KIR2DL5 (37) and evidence that the activation threshold of NK cells may be modulated via the co-expression of an aKIR [as shown for KIR2DL2/3 + NK cells which may recognize C2 targets in the presence of KIR2DS1 (10)], further clinical studies are urgently needed that incorporate a thorough phenotypical and functional NK cell characterization into analysis-not only on the clonal NK cell population level but also on the entire pool of alloreactive NK cells-to delineate the various effects of aKIRs in recognizing and targeting leukemia. As aKIR-HLA-class I interactions are determined by variable tissue-specific HLA-class I expression, by varying affinities of KIRs to their cognate HLA-class I ligands (that remain partially undefined) and by varying peptide expression on those HLA-class I molecules (that have to a large extent not yet been identified), it is still a long way to go to understand the biological basis of aKIR functionality and to be able to answer the question of whether 'more' is really 'better'.
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Supplementary data are available at International Immunology Online. 
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